A multicenter open label study to explore the efficacy and tolerability of Tenofovir DF (TDF) (300 mg) in chronic hepatitis B, HBeAg positive or negative, patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment, defined as HBV-DNA levels greater than 10.000 copies/ml after an ADV or ADV+LAM treatment of greater than 48 weeks.

Trial Profile

A multicenter open label study to explore the efficacy and tolerability of Tenofovir DF (TDF) (300 mg) in chronic hepatitis B, HBeAg positive or negative, patients with suboptimal response to adefovir (ADV) or ADV/LAM treatment, defined as HBV-DNA levels greater than 10.000 copies/ml after an ADV or ADV+LAM treatment of greater than 48 weeks.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Dec 2012

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Adefovir; Lamivudine
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms OptiB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top